Clark A. Lindgren
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Clark A. Lindgren has a total of 28 co-authors. Here are the top co-authors by number of shared publications:
Elaine M. Marzluff
Department of Chemistry, Grinnell College, Grinnell, IA 50112, United States
2 shared publicationsAustin R. Graves
Department of Biology Grinnell College 1116 8th Avenue Grinnell, IA 50112, USA
1 shared publicationChristopher Ochoa
Department of Biology, Grinnell College, Grinnell, IA 50112, USA
1 shared publicationClaire I.C. Warrenfelt
Grinnell Coll, Dept Biol, Grinnell, IA 50112 USA
1 shared publicationDanica Bojovic
Department of Biology, Grinnell College, Grinnell, Iowa, USA
1 shared publicationEmily M. Kozik
Biology Department Grinnell College Grinnell IA USA
1 shared publication
Latest Publications
- 29 September 2023
- Published by Elsevier in Neuroscience
- Vol. 532, 103-112
Reduced Plasma-Membrane Calcium ATPase Activity and Extracellular Acidification Trigger Presynaptic Homeostatic Potentiation at the Mouse Neuromuscular Junction
- 29 September 2023
- Published by Elsevier in Neuroscience
- Vol. 532, 103-112
Reduced Plasma-Membrane Calcium ATPase Activity and Extracellular Acidification Trigger Presynaptic Homeostatic Potentiation at the Mouse Neuromuscular Junction
- Open Access
Quantitative determination of nitric oxide from tissue samples using liquid chromatography—Mass spectrometry
- 21 May 2021
- Published by Elsevier in Neuroscience
- Vol. 467, 188-200
Extracellular Protons Mediate Presynaptic Homeostatic Potentiation at the Mouse Neuromuscular Junction
- 21 May 2021
- Published by Elsevier in Neuroscience
- Vol. 467, 188-200
Extracellular Protons Mediate Presynaptic Homeostatic Potentiation at the Mouse Neuromuscular Junction
- 21 September 2020
- Published by Wiley in Journal of Neurochemistry
- Vol. 156 (1) , 38-47
Evidence of NAAG‐family tripeptide NAAG2 in the Drosophila nervous system
N‐acetylaspartylglutamate (NAAG) is a common neurotransmitter in the mammalian nervous system; however, it has never been reported in the nervous system of the fruit fly, Drosophila melanogaster. Using antiserum against NAAG, we localized NAAG‐like immunoreactivity to neurons in the ventral nerve cord and to type Is glutamatergic nerve terminals in larval neuromuscular junctions. Using liquid chromatography tandem mass spectrometry (LC‐MS), we failed to find NAAG but found the related peptide N‐acetylaspartylglutamylglutamate (NAAG2) in Drosophila CNS and body wall tissue. This is the first report of any NAAG‐family peptide in the nervous system of Drosophila and is also the first report of NAAG2 being present in a much higher concentration than NAAG in the nervous system of any species. Thus, the larval fruit fly presents an interesting model for the study of the functional role of NAAG2 of which very little is known – especially in the absence of an abundance of NAAG.
- 21 September 2020
- Published by Wiley in Journal of Neurochemistry
- Vol. 156 (1) , 38-47
Evidence of NAAG‐family tripeptide NAAG2 in the Drosophila nervous system
N‐acetylaspartylglutamate (NAAG) is a common neurotransmitter in the mammalian nervous system; however, it has never been reported in the nervous system of the fruit fly, Drosophila melanogaster. Using antiserum against NAAG, we localized NAAG‐like immunoreactivity to neurons in the ventral nerve cord and to type Is glutamatergic nerve terminals in larval neuromuscular junctions. Using liquid chromatography tandem mass spectrometry (LC‐MS), we failed to find NAAG but found the related peptide N‐acetylaspartylglutamylglutamate (NAAG2) in Drosophila CNS and body wall tissue. This is the first report of any NAAG‐family peptide in the nervous system of Drosophila and is also the first report of NAAG2 being present in a much higher concentration than NAAG in the nervous system of any species. Thus, the larval fruit fly presents an interesting model for the study of the functional role of NAAG2 of which very little is known – especially in the absence of an abundance of NAAG.
- 15 August 2018
- Published by Wolters Kluwer Health in NeuroReport
- Vol. 29 (12) , 1030-1035
Homocysteine sensitizes the mouse neuromuscular junction to oxidative stress by nitric oxide
Homocysteine (HCY), a redox-active metabolite of the methionine cycle, is of particular clinical interest because of its association with various neurodegenerative diseases including amyotrophic lateral sclerosis. It has been previously established that HCY exacerbates damage to motor neurons from reactive oxygen species (ROS) such as hydrogen peroxide. To assess the role of HCY at the mammalian neuromuscular junction, neurotransmission was monitored by electrophysiology at the mouse epitrochleoanconeus muscle. Preparations were preincubated in HCY before inducing ROS and recordings were taken before and after ROS treatment. In this study, HCY was observed to sensitize the neuromuscular junction to ROS-induced depression of spontaneous transmission frequency, an effect we found to be mediated by a N-methyl-D-aspartate receptor (NMDAR) and nitric oxide (NO). The NMDAR antagonist D, L-2-amino-5-phosphonopentanoic acid prevented the HCY-induced sensitization to oxidative stress. Disrupting NO activity with either the nitric oxide synthase I antagonist Nω-nitro-L-arginine methyl ester hydrochloride or the NO scavenger 2-(4-carboxyphenyl)-4,4,5,5-tetramethyl-imidazoline-1-oxyl-3-oxide potassium salt also prevented sensitization. Moreover, replacing HCY with the exogenous NO donor Diethylamine NONOate diethylammonium was sufficient to reconstitute the effects of HCY-induced sensitization to ROS. Interestingly, a novel secondary effect was observed where HCY itself depresses quantal content, an effect found to be mediated by NMDARs independently of nitric oxide and ROS. Collectively, these data present a novel model of two distinct pathways through which HCY alters neurotransmission at the neuromuscular junction. Characterizing HCY’s mechanism of action is of particular clinical relevance as many treatments for amyotrophic lateral sclerosis are centered on mitigating HCY-induced pathologies.
- 15 August 2018
- Published by Wolters Kluwer Health in NeuroReport
- Vol. 29 (12) , 1030-1035
Homocysteine sensitizes the mouse neuromuscular junction to oxidative stress by nitric oxide
Homocysteine (HCY), a redox-active metabolite of the methionine cycle, is of particular clinical interest because of its association with various neurodegenerative diseases including amyotrophic lateral sclerosis. It has been previously established that HCY exacerbates damage to motor neurons from reactive oxygen species (ROS) such as hydrogen peroxide. To assess the role of HCY at the mammalian neuromuscular junction, neurotransmission was monitored by electrophysiology at the mouse epitrochleoanconeus muscle. Preparations were preincubated in HCY before inducing ROS and recordings were taken before and after ROS treatment. In this study, HCY was observed to sensitize the neuromuscular junction to ROS-induced depression of spontaneous transmission frequency, an effect we found to be mediated by a N-methyl-D-aspartate receptor (NMDAR) and nitric oxide (NO). The NMDAR antagonist D, L-2-amino-5-phosphonopentanoic acid prevented the HCY-induced sensitization to oxidative stress. Disrupting NO activity with either the nitric oxide synthase I antagonist Nω-nitro-L-arginine methyl ester hydrochloride or the NO scavenger 2-(4-carboxyphenyl)-4,4,5,5-tetramethyl-imidazoline-1-oxyl-3-oxide potassium salt also prevented sensitization. Moreover, replacing HCY with the exogenous NO donor Diethylamine NONOate diethylammonium was sufficient to reconstitute the effects of HCY-induced sensitization to ROS. Interestingly, a novel secondary effect was observed where HCY itself depresses quantal content, an effect found to be mediated by NMDARs independently of nitric oxide and ROS. Collectively, these data present a novel model of two distinct pathways through which HCY alters neurotransmission at the neuromuscular junction. Characterizing HCY’s mechanism of action is of particular clinical relevance as many treatments for amyotrophic lateral sclerosis are centered on mitigating HCY-induced pathologies.
- Open Access
- 9 August 2013
- Published by Wiley in The Journal of Physiology
- Vol. 591 (19) , 4749-4764
Cyclooxygenase-2, prostaglandin E2 glycerol ester and nitric oxide are involved in muscarine-induced presynaptic enhancement at the vertebrate neuromuscular junction
• The synapse between a nerve and muscle, called the neuromuscular junction (NMJ), undergoes a biphasic modulation, a decrease followed by an increase, when muscarinic acetylcholine receptors are continuously activated. • The initial depression is caused by the endocannabinoid 2-arachidonylglycerol (2-AG), which is synthesized in and released from the muscle; 2-AG then activates cannabinoid receptors on the presynaptic nerve. • In the work presented here, we explored the mechanism responsible for the delayed enhancement, uncovering a role for the enzyme cyclooxygenase-2 and locating it in the glial cells at the NMJ called perisynaptic Schwann cells (PSCs) where it converts 2-AG into the glycerol ester of prostaglandin E2. • These results reveal a complex mechanism for regulating neurotransmitter release that involves the nerve, muscle and PSCs (i.e. the tripartite synapse) and may serve to ensure reliable neuromuscular transmission during periods of intense or long-term activity. Abstract Previous work has demonstrated that activation of muscarinic acetylcholine receptors at the lizard neuromuscular junction (NMJ) induces a biphasic modulation of evoked neurotransmitter release: an initial depression followed by a delayed enhancement. The depression is mediated by the release of the endocannabinoid 2-arachidonylglycerol (2-AG) from the muscle and its binding to cannabinoid type 1 receptors on the motor nerve terminal. The work presented here suggests that the delayed enhancement of neurotransmitter release is mediated by cyclooxygenase-2 (COX-2) as it converts 2-AG to the glycerol ester of prostaglandin E2 (PGE2-G). Using immunofluorescence, COX-2 was detected in the perisynaptic Schwann cells (PSCs) surrounding the NMJ. Pretreatment with either of the selective COX-2 inhibitors, nimesulide or DuP 697, prevents the delayed increase in endplate potential (EPP) amplitude normally produced by muscarine. In keeping with its putative role as a mediator of the delayed muscarinic effect, PGE2-G enhances evoked neurotransmitter release. Specifically, PGE2-G increases the amplitude of EPPs without altering that of spontaneous miniature EPPs. As shown previously for the muscarinic effect, the enhancement of evoked neurotransmitter release by PGE2-G depends on nitric oxide (NO) as the response is abolished by application of either NG-nitro-l-arginine methyl ester (l-NAME), an inhibitor of NO synthesis, or carboxy-PTIO, a chelator of NO. Intriguingly, the enhancement is not prevented by AH6809, a prostaglandin receptor antagonist, but is blocked by capsazepine, a TRPV1 and TRPM8 receptor antagonist. Taken together, these results suggest that the conversion of 2-AG to PGE2-G by COX-2 underlies the muscarine-induced enhancement of neurotransmitter release at the vertebrate NMJ.
- 9 August 2013
- Published by Wiley in The Journal of Physiology
- Vol. 591 (19) , 4749-4764
Open AccessCyclooxygenase-2, prostaglandin E2 glycerol ester and nitric oxide are involved in muscarine-induced presynaptic enhancement at the vertebrate neuromuscular junction
• The synapse between a nerve and muscle, called the neuromuscular junction (NMJ), undergoes a biphasic modulation, a decrease followed by an increase, when muscarinic acetylcholine receptors are continuously activated. • The initial depression is caused by the endocannabinoid 2-arachidonylglycerol (2-AG), which is synthesized in and released from the muscle; 2-AG then activates cannabinoid receptors on the presynaptic nerve. • In the work presented here, we explored the mechanism responsible for the delayed enhancement, uncovering a role for the enzyme cyclooxygenase-2 and locating it in the glial cells at the NMJ called perisynaptic Schwann cells (PSCs) where it converts 2-AG into the glycerol ester of prostaglandin E2. • These results reveal a complex mechanism for regulating neurotransmitter release that involves the nerve, muscle and PSCs (i.e. the tripartite synapse) and may serve to ensure reliable neuromuscular transmission during periods of intense or long-term activity. Abstract Previous work has demonstrated that activation of muscarinic acetylcholine receptors at the lizard neuromuscular junction (NMJ) induces a biphasic modulation of evoked neurotransmitter release: an initial depression followed by a delayed enhancement. The depression is mediated by the release of the endocannabinoid 2-arachidonylglycerol (2-AG) from the muscle and its binding to cannabinoid type 1 receptors on the motor nerve terminal. The work presented here suggests that the delayed enhancement of neurotransmitter release is mediated by cyclooxygenase-2 (COX-2) as it converts 2-AG to the glycerol ester of prostaglandin E2 (PGE2-G). Using immunofluorescence, COX-2 was detected in the perisynaptic Schwann cells (PSCs) surrounding the NMJ. Pretreatment with either of the selective COX-2 inhibitors, nimesulide or DuP 697, prevents the delayed increase in endplate potential (EPP) amplitude normally produced by muscarine. In keeping with its putative role as a mediator of the delayed muscarinic effect, PGE2-G enhances evoked neurotransmitter release. Specifically, PGE2-G increases the amplitude of EPPs without altering that of spontaneous miniature EPPs. As shown previously for the muscarinic effect, the enhancement of evoked neurotransmitter release by PGE2-G depends on nitric oxide (NO) as the response is abolished by application of either NG-nitro-l-arginine methyl ester (l-NAME), an inhibitor of NO synthesis, or carboxy-PTIO, a chelator of NO. Intriguingly, the enhancement is not prevented by AH6809, a prostaglandin receptor antagonist, but is blocked by capsazepine, a TRPV1 and TRPM8 receptor antagonist. Taken together, these results suggest that the conversion of 2-AG to PGE2-G by COX-2 underlies the muscarine-induced enhancement of neurotransmitter release at the vertebrate NMJ.
- 8 November 2012
- Published by Wiley in European Journal of Neuroscience
- Vol. 37 (1) , 118-129
Immunohistological and electrophysiological evidence that N‐acetylaspartylglutamate is a co‐transmitter at the vertebrate neuromuscular junction
Immunohistochemical studies previously revealed the presence of the peptide transmitter N‐acetylaspartylglutamate (NAAG) in spinal motor neurons, axons and presumptive neuromuscular junctions (NMJs). At synapses in the central nervous system, NAAG has been shown to activate the type 3 metabotropic glutamate receptor (mGluR3) and is inactivated by an extracellular peptidase, glutamate carboxypeptidase II. The present study tested the hypothesis that NAAG meets the criteria for classification as a co‐transmitter at the vertebrate NMJ. Confocal microscopy confirmed the presence of NAAG immunoreactivity and extended the resolution of the peptide's location in the lizard (Anolis carolinensis) NMJ. NAAG was localised to a presynaptic region immediately adjacent to postsynaptic acetylcholine receptors. NAAG was depleted by potassium‐induced depolarisation and by electrical stimulation of motor axons. The NAAG receptor, mGluR3, was localised to the presynaptic terminal consistent with NAAG's demonstrated role as a regulator of synaptic release at central synapses. In contrast, glutamate receptors, type 2 metabotropic glutamate receptor (mGluR2) and N‐methyl‐d‐aspartate, were closely associated with acetylcholine receptors in the postsynaptic membrane. Glutamate carboxypeptidase II, the NAAG‐inactivating enzyme, was identified exclusively in perisynaptic glial cells. This localisation was confirmed by the loss of immunoreactivity when these cells were selectively eliminated. Finally, electrophysiological studies showed that exogenous NAAG inhibited evoked neurotransmitter release by activating a group II metabotropic glutamate receptor (mGluR2 or mGluR3). Collectively, these data support the conclusion that NAAG is a co‐transmitter at the vertebrate NMJ.
- 8 November 2012
- Published by Wiley in European Journal of Neuroscience
- Vol. 37 (1) , 118-129
Immunohistological and electrophysiological evidence that N‐acetylaspartylglutamate is a co‐transmitter at the vertebrate neuromuscular junction
Immunohistochemical studies previously revealed the presence of the peptide transmitter N‐acetylaspartylglutamate (NAAG) in spinal motor neurons, axons and presumptive neuromuscular junctions (NMJs). At synapses in the central nervous system, NAAG has been shown to activate the type 3 metabotropic glutamate receptor (mGluR3) and is inactivated by an extracellular peptidase, glutamate carboxypeptidase II. The present study tested the hypothesis that NAAG meets the criteria for classification as a co‐transmitter at the vertebrate NMJ. Confocal microscopy confirmed the presence of NAAG immunoreactivity and extended the resolution of the peptide's location in the lizard (Anolis carolinensis) NMJ. NAAG was localised to a presynaptic region immediately adjacent to postsynaptic acetylcholine receptors. NAAG was depleted by potassium‐induced depolarisation and by electrical stimulation of motor axons. The NAAG receptor, mGluR3, was localised to the presynaptic terminal consistent with NAAG's demonstrated role as a regulator of synaptic release at central synapses. In contrast, glutamate receptors, type 2 metabotropic glutamate receptor (mGluR2) and N‐methyl‐d‐aspartate, were closely associated with acetylcholine receptors in the postsynaptic membrane. Glutamate carboxypeptidase II, the NAAG‐inactivating enzyme, was identified exclusively in perisynaptic glial cells. This localisation was confirmed by the loss of immunoreactivity when these cells were selectively eliminated. Finally, electrophysiological studies showed that exogenous NAAG inhibited evoked neurotransmitter release by activating a group II metabotropic glutamate receptor (mGluR2 or mGluR3). Collectively, these data support the conclusion that NAAG is a co‐transmitter at the vertebrate NMJ.
- Open Access
- 1 March 2007
- Published by Wiley in European Journal of Neuroscience
- Vol. 25 (6) , 1619-1630
Endocannabinoids mediate muscarine‐induced synaptic depression at the vertebrate neuromuscular junction
Endocannabinoids (eCBs) inhibit neurotransmitter release throughout the central nervous system. Using theCeratomandibularismuscle from the lizardAnolis carolinensiswe asked whether eCBs play a similar role at the vertebrate neuromuscular junction. We report here that the CB1cannabinoid receptor is concentrated on motor terminals and that eCBs mediate the inhibition of neurotransmitter release induced by the activation of M3muscarinic acetylcholine (ACh) receptors.N‐(piperidin‐1‐yl)‐5‐(4‐iodophenyl)‐1‐(2,4‐dichlorophenyl)‐4‐methyl‐1H‐pyrazole‐3‐carboxamide, a CB1antagonist, prevents muscarine from inhibiting release and arachidonylcyclopropylamide (ACPA), a CB1receptor agonist, mimics M3activation and occludes the effect of muscarine. As for its mechanism of action, ACPA reduces the action‐potential‐evoked calcium transient in the nerve terminal and this decrease is more than sufficient to account for the observed inhibition of neurotransmitter release. Similar to muscarine, the inhibition of synaptic transmission by ACPA requires nitric oxide, acting via the synthesis of cGMP and the activation of cGMP‐dependent protein kinase. 2‐Arachidonoylglycerol (2‐AG) is responsible for the majority of the effects of eCB as inhibitors of phospholipase C and diacylglycerol lipase, two enzymes responsible for synthesis of 2‐AG, significantly limit muscarine‐induced inhibition of neurotransmitter release. Lastly, the injection of (5Z,8Z,11Z,14Z)‐N‐(4‐hydroxy‐2‐methylphenyl)‐5,8,11,14‐eicosatetraenamide (an inhibitor of eCB transport) into the muscle prevents muscarine, but not ACPA, from inhibiting ACh release. These results collectively lead to a model of the vertebrate neuromuscular junction whereby 2‐AG mediates the muscarine‐induced inhibition of ACh release. To demonstrate the physiological relevance of this model we show that the CB1antagonistN‐(piperidin‐1‐yl)‐5‐(4‐iodophenyl)‐1‐(2,4‐dichlorophenyl)‐4‐methyl‐1H‐pyrazole‐3‐carboxamide prevents synaptic inhibition induced by 20 min of 1‐Hz stimulation.
- 1 March 2007
- Published by Wiley in European Journal of Neuroscience
- Vol. 25 (6) , 1619-1630
Open AccessEndocannabinoids mediate muscarine‐induced synaptic depression at the vertebrate neuromuscular junction
Endocannabinoids (eCBs) inhibit neurotransmitter release throughout the central nervous system. Using theCeratomandibularismuscle from the lizardAnolis carolinensiswe asked whether eCBs play a similar role at the vertebrate neuromuscular junction. We report here that the CB1cannabinoid receptor is concentrated on motor terminals and that eCBs mediate the inhibition of neurotransmitter release induced by the activation of M3muscarinic acetylcholine (ACh) receptors.N‐(piperidin‐1‐yl)‐5‐(4‐iodophenyl)‐1‐(2,4‐dichlorophenyl)‐4‐methyl‐1H‐pyrazole‐3‐carboxamide, a CB1antagonist, prevents muscarine from inhibiting release and arachidonylcyclopropylamide (ACPA), a CB1receptor agonist, mimics M3activation and occludes the effect of muscarine. As for its mechanism of action, ACPA reduces the action‐potential‐evoked calcium transient in the nerve terminal and this decrease is more than sufficient to account for the observed inhibition of neurotransmitter release. Similar to muscarine, the inhibition of synaptic transmission by ACPA requires nitric oxide, acting via the synthesis of cGMP and the activation of cGMP‐dependent protein kinase. 2‐Arachidonoylglycerol (2‐AG) is responsible for the majority of the effects of eCB as inhibitors of phospholipase C and diacylglycerol lipase, two enzymes responsible for synthesis of 2‐AG, significantly limit muscarine‐induced inhibition of neurotransmitter release. Lastly, the injection of (5Z,8Z,11Z,14Z)‐N‐(4‐hydroxy‐2‐methylphenyl)‐5,8,11,14‐eicosatetraenamide (an inhibitor of eCB transport) into the muscle prevents muscarine, but not ACPA, from inhibiting ACh release. These results collectively lead to a model of the vertebrate neuromuscular junction whereby 2‐AG mediates the muscarine‐induced inhibition of ACh release. To demonstrate the physiological relevance of this model we show that the CB1antagonistN‐(piperidin‐1‐yl)‐5‐(4‐iodophenyl)‐1‐(2,4‐dichlorophenyl)‐4‐methyl‐1H‐pyrazole‐3‐carboxamide prevents synaptic inhibition induced by 20 min of 1‐Hz stimulation.
- 25 August 2004
- Published by Wiley in The Journal of Physiology
- Vol. 559 (2) , 423-432
Nitric oxide, cAMP and the biphasic muscarinic modulation of ACh release at the lizard neuromuscular junction
In this study, we characterized the pharmacology and physiology of the automodulation of ACh release at the lizard neuromuscular junction (NMJ). The activation of muscarinic ACh receptors generated a biphasic modulation of synaptic transmission. Muscarine‐induced activation of M3 receptors (0–12 min) decreased release, whereas M1 activation (> 12 min) enhanced release. Both phases of the biphasic effect are dependent on nitric oxide. However, cAMP acting via protein kinase A is also necessary for the M1 effect. In summary, we present a novel biphasic role for muscarine and implicate M3 receptors in the inhibition and M1 receptors in the enhancement of transmitter releaseat the cholinergic lizard NMJ.
- 25 August 2004
- Published by Wiley in The Journal of Physiology
- Vol. 559 (2) , 423-432
Nitric oxide, cAMP and the biphasic muscarinic modulation of ACh release at the lizard neuromuscular junction
In this study, we characterized the pharmacology and physiology of the automodulation of ACh release at the lizard neuromuscular junction (NMJ). The activation of muscarinic ACh receptors generated a biphasic modulation of synaptic transmission. Muscarine‐induced activation of M3 receptors (0–12 min) decreased release, whereas M1 activation (> 12 min) enhanced release. Both phases of the biphasic effect are dependent on nitric oxide. However, cAMP acting via protein kinase A is also necessary for the M1 effect. In summary, we present a novel biphasic role for muscarine and implicate M3 receptors in the inhibition and M1 receptors in the enhancement of transmitter releaseat the cholinergic lizard NMJ.